Literature DB >> 27398093

Transmissible cancers, are they more common than thought?

Beata Ujvari1, Robert A Gatenby2, Frédéric Thomas3.   

Abstract

Entities:  

Keywords:  Tasmanian devil; ecology; evolution; transmissible cancer

Year:  2016        PMID: 27398093      PMCID: PMC4869404          DOI: 10.1111/eva.12372

Source DB:  PubMed          Journal:  Evol Appl        ISSN: 1752-4571            Impact factor:   5.183


× No keyword cloud information.
Although many cancers are associated with infectious agents (Ewald and Swain Ewald 2015), only four naturally occurring transmissible cancers have so far been identified in dogs, soft‐shell clams and Tasmanian devils (DFT1 and DFT2) (Pye et al. 2015). The recent discovery of DFT2 (Pye et al. 2015) provides an intriguing story to the evolution of transmissible cancers and poses several questions:

How could two transmissible cancers emerge in the same species?

Cancer cell transmission to a new host is, like the metastatic cascade, a complex multistep process, with distinct micro‐ and macro‐environmental barriers (Gatenby and Gillies 2008). A crucial step of cancer cell transmission requires the tumour cells to overcome histocompatibility barriers, which is highly facilitated by the reduced genetic diversity of devils. Furthermore, DFTD has originated form peripheral nerve cells that possess the astonishing capacity to reverse functional and developmental commitments (Masaki et al. 2013). The combination of a permissive host micro‐environment and highly plastic cells of origin could have provided several cells to sabotage multicellularity, enter a selfish lifestyle and become transmissible malignant cell lineages.

How will the two DFT variants evolve?

It seems unlikely that DFT2 arose from DFT1 even though the temporal sequence of their discovery suggests it. That is, it is difficult to imagine that the chromosome fragments in DFT1 coalescing into the relatively normal DFT2 karyotype. The other direction (i.e. DFT2 evolving into DFT1) seems plausible, or most likely, the two diseases have arose separately. An important question is whether the DFT2 tumour is slower growing than DFT1. As the latter seems to grow very quickly, rapidly kill the animals and decimate the host population, the time of potential transmission is short. In this setting, a slower growing tumour may be fitter as the slower growth permits a longer time for transmission in an increasingly sparse population. It will be interesting to see whether slower growing phenotypes become more prevalent as the population steadily declines (Ujvari et al. 2014). The epidemic may actually select for less aggressive tumour phenotypes, and DFTD perhaps will ultimately evolve into a relatively benign tumour. Importantly, according to the speciation theory of cancer evolution, cancers, particularly transmissible ones, could represent new cellular species (Duesberg et al. 2011).

Are transmissible cancers rare?

We propose that the emergence of transmissible cancers requires a ‘perfect storm’ with the rare confluence of multiple host and tumour cell traits (Ujvari et al. 2016). At least four key factors are required: (i) shedding of tumour cells from the affected host, (ii) survival of tumour cells during the host–host transit, (iii) a permissive environment facilitating invasion and (iv) adaptation to novel habitats and evasion of immune attacks in the foreign host. While this rare confluence of traits explains the rarity of tumour cell transmission, it also suggests that when it eventuates, multiple emergences can theoretically happen as long as the favourable window persists. It is possible that during the eons of evolution, several contagious cancers have evolved, but due to their detrimental impact on host fitness, selection has eliminated them, as well as they might have driven their hosts to extinctions. Consequently, it is conceivable that due to our limited perception of the evolutionary timescale, we fail to recognize extinct contagious cancers and hence erroneously identify them to be rare.
  7 in total

1.  Is carcinogenesis a form of speciation?

Authors:  Peter Duesberg; Daniele Mandrioli; Amanda McCormack; Joshua M Nicholson
Journal:  Cell Cycle       Date:  2011-07-01       Impact factor: 4.534

2.  A second transmissible cancer in Tasmanian devils.

Authors:  Ruth J Pye; David Pemberton; Cesar Tovar; Jose M C Tubio; Karen A Dun; Samantha Fox; Jocelyn Darby; Dane Hayes; Graeme W Knowles; Alexandre Kreiss; Hannah V T Siddle; Kate Swift; A Bruce Lyons; Elizabeth P Murchison; Gregory M Woods
Journal:  Proc Natl Acad Sci U S A       Date:  2015-12-28       Impact factor: 11.205

Review 3.  The evolutionary ecology of transmissible cancers.

Authors:  Beata Ujvari; Robert A Gatenby; Frédéric Thomas
Journal:  Infect Genet Evol       Date:  2016-02-06       Impact factor: 3.342

Review 4.  Infection and cancer in multicellular organisms.

Authors:  Paul W Ewald; Holly A Swain Ewald
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-07-19       Impact factor: 6.237

5.  Reprogramming adult Schwann cells to stem cell-like cells by leprosy bacilli promotes dissemination of infection.

Authors:  Toshihiro Masaki; Jinrong Qu; Justyna Cholewa-Waclaw; Karen Burr; Ryan Raaum; Anura Rambukkana
Journal:  Cell       Date:  2013-01-17       Impact factor: 41.582

Review 6.  A microenvironmental model of carcinogenesis.

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2008-01       Impact factor: 60.716

7.  Anthropogenic selection enhances cancer evolution in Tasmanian devil tumours.

Authors:  Beata Ujvari; Anne-Maree Pearse; Kate Swift; Pamela Hodson; Bobby Hua; Stephen Pyecroft; Robyn Taylor; Rodrigo Hamede; Menna Jones; Katherine Belov; Thomas Madsen
Journal:  Evol Appl       Date:  2013-11-06       Impact factor: 5.183

  7 in total
  7 in total

Review 1.  Population genetics of clonally transmissible cancers.

Authors:  Máire Ní Leathlobhair; Richard E Lenski
Journal:  Nat Ecol Evol       Date:  2022-07-25       Impact factor: 19.100

2.  Weird genotypes? Don't discard them, transmissible cancer could be an explanation.

Authors:  Florentine Riquet; Alexis Simon; Nicolas Bierne
Journal:  Evol Appl       Date:  2016-12-16       Impact factor: 5.183

3.  Transmissible cancer and the evolution of sex.

Authors:  Frédéric Thomas; Thomas Madsen; Mathieu Giraudeau; Dorothée Misse; Rodrigo Hamede; Orsolya Vincze; François Renaud; Benjamin Roche; Beata Ujvari
Journal:  PLoS Biol       Date:  2019-06-06       Impact factor: 8.029

Review 4.  Group phenotypic composition in cancer.

Authors:  Jean-Pascal Capp; James DeGregori; Aurora M Nedelcu; Beata Ujvari; Andriy Marusyk; Robert Gatenby; Frédéric Thomas; Antoine M Dujon; Justine Boutry; Pascal Pujol; Catherine Alix-Panabières; Rodrigo Hamede; Benjamin Roche
Journal:  Elife       Date:  2021-03-30       Impact factor: 8.140

5.  Identifying key questions in the ecology and evolution of cancer.

Authors:  Antoine M Dujon; Athena Aktipis; Catherine Alix-Panabières; Sarah R Amend; Amy M Boddy; Joel S Brown; Jean-Pascal Capp; James DeGregori; Paul Ewald; Robert Gatenby; Marco Gerlinger; Mathieu Giraudeau; Rodrigo K Hamede; Elsa Hansen; Irina Kareva; Carlo C Maley; Andriy Marusyk; Nicholas McGranahan; Michael J Metzger; Aurora M Nedelcu; Robert Noble; Leonard Nunney; Kenneth J Pienta; Kornelia Polyak; Pascal Pujol; Andrew F Read; Benjamin Roche; Susanne Sebens; Eric Solary; Kateřina Staňková; Holly Swain Ewald; Frédéric Thomas; Beata Ujvari
Journal:  Evol Appl       Date:  2021-02-08       Impact factor: 5.183

6.  Genotype data not consistent with clonal transmission of sea turtle fibropapillomatosis or goldfish schwannoma.

Authors:  Máire Ní Leathlobhair; Kelsey Yetsko; Jessica A Farrell; Carmelo Iaria; Gabriele Marino; David J Duffy; Elizabeth P Murchison
Journal:  Wellcome Open Res       Date:  2021-09-02

7.  Transmissible cancers and the evolution of sex under the Red Queen hypothesis.

Authors:  Thomas G Aubier; Matthias Galipaud; E Yagmur Erten; Hanna Kokko
Journal:  PLoS Biol       Date:  2020-11-19       Impact factor: 8.029

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.